- Home
- INMB vs ALGS Comparison
INMB vs ALGS Comparison
Compare INMB & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ALGS
- Stock Information
- Founded
- INMB 2015
- ALGS 2018
- Country
- INMB United States
- ALGS United States
- Employees
- INMB N/A
- ALGS N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- ALGS Health Care
- Exchange
- INMB Nasdaq
- ALGS Nasdaq
- Market Cap
- INMB 53.4M
- ALGS 53.0M
- IPO Year
- INMB 2019
- ALGS 2020
- Fundamental
- Price
- INMB $1.97
- ALGS $9.37
- Analyst Decision
- INMB Buy
- ALGS Strong Buy
- Analyst Count
- INMB 4
- ALGS 2
- Target Price
- INMB $9.53
- ALGS $60.00
- AVG Volume (30 Days)
- INMB 827.8K
- ALGS 73.3K
- Earning Date
- INMB 10-30-2025
- ALGS 11-05-2025
- Dividend Yield
- INMB N/A
- ALGS N/A
- EPS Growth
- INMB N/A
- ALGS N/A
- EPS
- INMB N/A
- ALGS N/A
- Revenue
- INMB $50,000.00
- ALGS $3,174,000.00
- Revenue This Year
- INMB $142.83
- ALGS N/A
- Revenue Next Year
- INMB $14,780.90
- ALGS $28.79
- P/E Ratio
- INMB N/A
- ALGS N/A
- Revenue Growth
- INMB N/A
- ALGS N/A
- 52 Week Low
- INMB $1.71
- ALGS $3.76
- 52 Week High
- INMB $11.64
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- INMB 39.67
- ALGS 44.31
- Support Level
- INMB $1.71
- ALGS $10.66
- Resistance Level
- INMB $2.00
- ALGS $11.65
- Average True Range (ATR)
- INMB 0.14
- ALGS 0.85
- MACD
- INMB 0.04
- ALGS -0.18
- Stochastic Oscillator
- INMB 44.07
- ALGS 3.72
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.